IPO Calendar
Lead Manager
- J P Morgan Chase (471)
- Goldman Sachs (447)
- Morgan Stanley (400)
- Bank of America Merrill Lynch (347)
- Citigroup (217)
- Jefferies (204)
- Credit Suisse (180)
- Barclays (142)
- Cowen and Company (140)
- Deutsche Bank (81)
- Piper Jaffray (70)
- Leerink Partners (68)
- Stifel (61)
- UBS Investment Bank (50)
- RBC Capital (49)
- Evercore (49)
- BMO Capital (48)
- Wells Fargo (44)
- William Blair (36)
- Raymond James (34)
More +
IPO - Pricing (68)
LeerinkPartners
UnderWriters* | |||||||||||
Date | Company Name | Sector | Price ($) |
Size (M) |
1 | 2 | 3 | Rank | Turnover | Gain | |
---|---|---|---|---|---|---|---|---|---|---|---|
Nov 14 | FibroGen Inc | Health-Care | 18 | 8 | CITI | GS | LRNK | 79.5% | 22.2% | ||
Oct 22 | DBV Technologie | Health-Care | 21.6 | 4 | CITI | LRNK | 29% | 5.8% | |||
Oct 15 | Forward Pharma | Health-Care | 21 | 10 | JEFF | LRNK | RBC | 38.7% | -16.7% | ||
Oct 3 | Journey Medical | Health-Care | 16 | 7 | CITI | LRNK | 72.1% | -2.8% | |||
Oct 2 | Calithera Biosc | Health-Care | 10 | 8 | CITI | LRNK | 57.9% | -5.9% | |||
Sep 18 | ProQR Therapeut | Health-Care | 13 | 7 | DB | LRNK | 90.1% | 13.3% | |||
Sep 12 | Affimed N.V. | Health-Care | 7 | 8 | BMO | JEFF | LRNK | 44.6% | -18.6% | ||
Jul 17 | CareDx Inc. | Health-Care | 10 | 4 | LRNK | PPRJ | 39.9% | -9.5% | |||
Jun 19 | Ardelyx Inc. | Health-Care | 14 | 4 | CITI | LRNK | 36.9% | 0.8% | |||
Feb 5 | uniQure N.V. | Health-Care | 17 | 5 | JEFF | LRNK | LRNK | 86.8% | -14.1% | ||
Nov 11 | WAVE Life Scien | Health-Care | 16 | 6 | JEFF | LRNK | 21.4% | 0% | |||
Nov 5 | Kura Oncology I | Health-Care | 8 | 6 | CITI | LRNK | 12.6% | -2% | |||
Sep 18 | Nabriva Therape | Health-Care | 10.3 | 9 | LRNK | RBC | 21.2% | 29.2% | |||
May 6 | HTG Molecular D | Capital-Goods | 14 | 3 | LRNK | 25.4% | -1.6% | ||||
May 6 | Adaptimmune The | Health-Care | 17 | 11 | BAML | COWN | LRNK | 73.8% | -5.9% | ||
Apr 15 | Cidara Therapeu | Health-Care | 16 | 4 | JEFF | LRNK | 94% | 0% | |||
Feb 13 | Bellerophon The | Health-Care | 12 | 5 | COWN | LRNK | 30.6% | -25.3% | |||
Jan 28 | Ascendis Pharma | Health-Care | 18 | 6 | BAML | LRNK | 58.5% | 4.6% | |||
Sep 23 | AC Immune SA | Health-Care | 11 | 6 | CS | JEFF | LRNK | 62.9% | 42.4% | ||
Jun 5 | Intellia Therap | Health-Care | 18 | 6 | CS | JEFF | LRNK | 83.7% | 22.8% | ||
Mar 18 | Senseonics Hold | Capital-Goods | 2.9 | 15 | CNCD | LRNK | 7.3% | 0% | |||
Dec 7 | Quanterix Corpo | Capital-Goods | 15 | 4 | JPM | LRNK | 54.9% | 16.5% | |||
Nov 17 | scPharmaceutica | Health-Care | 14 | 6.4M | JEFF | LRNK | BMO | 15.6% | 0.7% | ||
Sep 20 | Zai Lab Limited | Health-Care | 18 | 8 | JPM | CITI | LRNK | 60.6% | 55.2% | ||
Jun 28 | Mersana Therape | Health-Care | 15 | 5 | JPM | COWN | LRNK | 54% | -6.7% | ||
Jan 26 | ObsEva SA | Health-Care | 15 | 6 | CS | JEFF | LRNK | 50.9% | -22.3% | ||
Oct 12 | Equillium Inc. | Health-Care | 14 | 4 | JEFF | LRNK | 19.6% | 0% | |||
Jul 20 | Replimune Group | Health-Care | 15 | 6 | BMO | JPM | LRNK | 46.6% | 1.1% | ||
Jul 18 | Crinetics Pharm | Health-Care | 17 | 6 | JPM | LRNK | PPRJ | 60% | 44.2% | ||
Jun 21 | Xeris Pharmaceu | Health-Care | 15 | 5 | JEFF | LRNK | RBC | 36.3% | 34.8% | ||
May 25 | Iterum Therapeu | Health-Care | 13 | 6 | LRNK | RBC | 11.9% | -1.2% | |||
May 4 | ASLAN Pharmaceu | Health-Care | 7 | 6 | LRNK | PPRJ | 13.6% | -20.2% | |||
Mar 15 | Arcus Bioscienc | Health-Care | 15 | 8 | CITI | GS | LRNK | 70% | 13.3% | ||
Jan 26 | Solid Bioscienc | Health-Care | 16 | 7 | GS | JPM | LRNK | 42.3% | 41.4% | ||
Dec 3 | Xencor Inc | Health-Care | 5.5 | 12 | CS | LRNK | 14.7% | 51.6% | |||
Nov 6 | Karyopharm Ther | Health-Care | 16 | 6 | BAML | LRNK | MS | 87.5% | 0.3% | ||
Oct 30 | Veracyte Inc | Health-Care | 13 | 5 | LRNK | MS | 91.9% | 1.9% | |||
Oct 10 | MacroGenics Inc | Health-Care | 16 | 5 | BAML | LRNK | 107.2% | 56.2% | |||
Jul 25 | Onconova Therap | Health-Care | 15 | 5 | CITI | LRNK | 0.7% | 98.7% | |||
May 31 | Epizyme Inc | Health-Care | 15 | 5 | CITI | COWN | LRNK | 63.9% | 53.3% | ||
Feb 8 | Harpoon Therape | NA | 14 | 5 | CITI | LRNK | 24.3% | -3.6% | |||
Feb 8 | Gossamer Bio In | NA | 16 | 17 | BAML | LRNK | BRCL | 34.2% | 12.1% | ||
Jul 21 | Turnstone Biolo | Health Care | 12 | 6 | BAML | LRNK | PPRJ | 17.2% | -8.3% | ||
May 7 | Trevi Therapeut | NA | 10 | 5 | LRNK | Stifel | BMO | 24.9% | -21.1% | ||
Jul 18 | Fulcrum Therape | Health-Care | 16 | 4 | MS | BAML | LRNK | 27.6% | -15.6% | ||
Jul 25 | Castle Bioscien | Health-Care | 16 | 4 | LRNK | BARD | 53.9% | 33.8% | |||
Nov 7 | Centogene B.V. | Health-Care | 14 | 4 | LRNK | EVCR | 23.2% | -10.8% | |||
Nov 11 | 89bio Inc. | Health-Care | 16 | 5 | BAML | LRNK | RBC | 4.6% | 30% | ||
Apr 17 | Turning Point T | NA | 18 | 9 | GS | LRNK | WLFG | 34.2% | 60.6% | ||
Mar 12 | IMARA Inc. | Health-Care | 16 | 4 | MS | CITI | LRNK | 9.7% | -6.3% | ||
Apr 8 | Keros Therapeut | Health-Care | 16 | 6 | JEFF | LRNK | 17.7% | 25.5% | |||
Jun 5 | Applied Molecul | Health-Care | 14 | 11 | BAML | JEFF | LRNK | 31.6% | 28.4% | ||
Jun 19 | Forma Therapeut | Health-Care | 20 | 13 | JEFF | LRNK | CS | 11.3% | 95% | ||
Jul 30 | AlloVir Inc. | Health-Care | 17 | 16 | MS | JPM | LRNK | 2.5% | 46.5% | ||
Jul 24 | iTeos Therapeut | Health-Care | 19 | 10 | JPM | LRNK | 22.2% | 0.3% | |||
Sep 25 | Graybug Vision | Health-Care | 16 | 5 | LRNK | SNDL | 34.6% | 3.1% | |||
Oct 29 | Galecto Inc. | Health-Care | 15 | 5 | BAML | LRNK | CS | 23.4% | 0% | ||
Dec 3 | Kinnate BioPhar | Health-Care | 20 | 12 | GS | LRNK | PPRJ | 5.3% | 117.3% | ||
Dec 4 | Silverback Ther | Health-Care | 21 | 11 | GS | LRNK | Stifel | 31% | 19% | ||
Dec 18 | 908 Devices Inc | Health-Care | 20 | 6 | COWN | LRNK | Stifel | 64.9% | 145% | ||
Jan 8 | Cullinan Oncolo | Health-Care | 29.9 | 21 | MS | LRNK | EVCR | 19.3% | 0% | ||
Feb 5 | Pharvaris B.V. | Health-Care | 20 | 8 | MS | BAML | LRNK | 46% | 45% | ||
Jan 7 | Amylyx Pharmace | Health-Care | 19 | 10 | GS | LRNK | EVCR | 21.6% | -4.9% | ||
Oct 20 | Abivax S.A. | Health Care | 11.6 | 18 | MS | LRNK | 16% | -28.4% | |||
Nov 3 | Lexeo Therapeut | Health Care | 11 | 9 | JPM | LRNK | RBC | 12.6% | -8.6% | ||
Feb 8 | Kyverna Therape | Health Care | 22 | 14 | JPM | MS | LRNK | 4.4% | 36.8% | ||
Feb 9 | Helix Acquisiti | Finance | 10 | 16 | LRNK | 30.5% | 1.9% | ||||
Mar 28 | Boundless Bio, | Health Care | 16 | 6 | GS | LRNK | PS | 27.8% | -10.9% |
*
Lead manager or one of top three managers in an underwriting team.